New injection shows promise for liver failure in early trial
NCT ID NCT05689645
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial is testing an experimental drug called F573 in 97 people with acute liver failure or acute-on-chronic liver failure. Participants receive daily injections of F573 or a placebo for 7 days. The main goal is to check safety and side effects, while also looking at survival and liver function. The study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- F573 injection
- What this could lead to
- If successful, this could point toward a new treatment option for acute liver failure or acute-on-chronic liver failure, potentially improving survival and reducing need for transplant.
- What could go wrong
- This is an early Phase 2 trial with only 97 participants, so results may not apply to all patients. The drug is still experimental, and safety and effectiveness are not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LIVER FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hospital of Southwest Medical University
RECRUITINGLuzhou, Sichuan, China
-
Beijing You 'an Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, China
-
First Hospital of Jilin University
RECRUITINGChangchun, Jilin, China
-
Heze Municipal Hospital
RECRUITINGHeze, Shandong, China
-
Hunan Medical College General Hospital (formerly Huaihua City First People's Hospital)
RECRUITINGHuaihua, Hunan, China
-
Pingxiang Second People's Hospital
RECRUITINGPingxiang, Jiangxi P, China
-
Qingyuan People's Hospital (Sixth Affiliated Hospital of Guangzhou Medical University)
RECRUITINGQingyuan, Guangdong, China
-
Shanxi Bethune Hospital
RECRUITINGTaiyuan, Shanxi, China
-
Shiyan City Taihe Hospital
RECRUITINGShiyan, Hubei, China
-
The Affiliated Hospital of Binzhou Medical University
RECRUITINGBinzhou, Shandong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Can a common antioxidant rescue failing livers?
- Can a new injection tame chronic hepatitis b?
- Double liver trouble: does having both hepatitis b and fatty liver speed up disease?
- A second punch against hepatitis b: interferon after RNA drugs may clear the virus
- Could common hepatitis b drugs damage kidneys? a study digs into the data